Key Points
- Exelixis EVP Patrick Haley sold 28,043 shares on Nov. 21 at an average price of $42.58 for proceeds of about $1.19M, reducing his holding by 6.97% to 374,029 shares (SEC filing).
- Exelixis beat quarterly expectations with $0.78 EPS (vs. $0.68) and revenue of $597.8M, up 10.8% year-over-year, and analysts forecast roughly 2.04 EPS for the current fiscal year.
- The stock carries a consensus rating of “Moderate Buy” with a $45.45 target, trading near $42 and a market cap of approximately $11.33 billion.
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Patrick Haley sold 28,043 shares of the company's stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $42.58, for a total transaction of $1,194,070.94. Following the completion of the sale, the executive vice president owned 374,029 shares of the company's stock, valued at approximately $15,926,154.82. This trade represents a 6.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Exelixis Stock Performance
NASDAQ EXEL opened at $42.25 on Tuesday. The firm's 50 day moving average price is $39.93 and its two-hundred day moving average price is $40.73. Exelixis, Inc. has a twelve month low of $31.90 and a twelve month high of $49.62. The stock has a market cap of $11.33 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 0.79 and a beta of 0.32.
Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.68 by $0.10. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $597.76 million during the quarter, compared to analysts' expectations of $590.04 million. During the same quarter last year, the firm posted $0.47 earnings per share. Exelixis's revenue was up 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. On average, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC boosted its holdings in Exelixis by 9.1% in the third quarter. CIBC Private Wealth Group LLC now owns 6,065 shares of the biotechnology company's stock worth $250,000 after purchasing an additional 508 shares in the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Exelixis during the 3rd quarter worth about $357,000. Center For Asset Management LLC acquired a new position in shares of Exelixis during the 3rd quarter valued at about $511,000. Captrust Financial Advisors increased its holdings in shares of Exelixis by 6.4% during the 3rd quarter. Captrust Financial Advisors now owns 75,293 shares of the biotechnology company's stock valued at $3,110,000 after acquiring an additional 4,547 shares during the last quarter. Finally, Danske Bank A S bought a new position in shares of Exelixis in the 3rd quarter valued at approximately $9,749,000. Institutional investors own 85.27% of the company's stock.
Analyst Ratings Changes
EXEL has been the topic of several research analyst reports. Leerink Partnrs raised Exelixis from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 21st. Oppenheimer reiterated a "market perform" rating and issued a $36.00 price objective on shares of Exelixis in a research note on Wednesday, November 5th. Truist Financial decreased their target price on shares of Exelixis from $56.00 to $49.00 and set a "buy" rating for the company in a research note on Tuesday, July 29th. William Blair reaffirmed an "outperform" rating on shares of Exelixis in a research note on Tuesday, July 29th. Finally, Wolfe Research began coverage on Exelixis in a report on Tuesday, November 18th. They set a "peer perform" rating for the company. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and twelve have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $45.45.
Get Our Latest Stock Analysis on EXEL
Exelixis Company Profile
(
Get Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
